Packages (Simulation)
Certificate
OneStep ELISA Kit for Immunoglobulin G4 (IgG4)
IGHG4; Ig Gamma-4 Chain C Region; Immunoglobulin Heavy Constant Gamma 4; G4m Marker; Immunoglobulin Gm4
- Product No.OEA234Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample Typeserum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length1h10min
- Detection Range0.156-10ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.058ng/mL.
- DownloadInstruction Manual
- UOM 48T96T
- FOB
US$ 485
US$ 693
For more details, please contact local distributors!
Specificity
This assay has high sensitivity and excellent specificity for detection of Immunoglobulin G4 (IgG4).
No significant cross-reactivity or interference between Immunoglobulin G4 (IgG4) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Immunoglobulin G4 (IgG4) and the recovery rates were calculated by comparing the measured value to the expected amount of Immunoglobulin G4 (IgG4) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 95-102 | 99 |
| EDTA plasma(n=5) | 80-96 | 86 |
| heparin plasma(n=5) | 78-91 | 87 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Immunoglobulin G4 (IgG4) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Immunoglobulin G4 (IgG4) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Immunoglobulin G4 (IgG4) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 83-92% | 92-105% | 89-97% | 81-93% |
| EDTA plasma(n=5) | 84-104% | 89-103% | 90-97% | 90-98% |
| heparin plasma(n=5) | 92-105% | 96-105% | 84-101% | 81-99% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 50µL standard or sample to each well, then add 50µL prepared Detection Reagent A to each well. Incubate 1 hour at 37°C;
3. Aspirate and wash 3 times;
4. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
5. Add 50µL Stop Solution. Read at 450nm immediately.
GIVEAWAYS
INCREMENT SERVICES
| Magazine | Citations |
| BioMed Research International | The Effect of CXC Motif Chemokine 13 on Hepatocellular Carcinoma Associates with Wnt Signaling Hindawi:Source |
| Adv Med Sci. | Utility of serum IgG, IgG4 and carbonic anhydrase II antibodies in distinguishing autoimmune pancreatitis from pancreatic cancer and chronic pancreatitis Pubmed:25194335 |
| Oncology Reports | Beneficial effect of T follicular helper cells on antibody class switching of B cells in prostate cancer Pubmed:25529861 |
| Iranian Journal of Pharmaceutical Research | Effect of Cysteamine on Cell Growth and IgG4 Production in Recombinant Sp2.0 Cells Pubmed:25561924 |
| Ann Hematol | Loss of interleukin-21 leads to atrophic germinal centers in multicentric Castleman’s disease PubMed: 26377996 |
| Biomed Res Int | The Effect of C-X-C Motif Chemokine 13 on Hepatocellular Carcinoma Associates with Wnt Signaling PubMed: 26161394 |
| 网页进不去,NCBI上搜不到 | Increasing Foxp3, IgG4 and improvement quality of life after immunotherapy treatment in allergic rhinitis patients article:30785 |


